Reading MLYS? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track MLYS free→Reading MLYS? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track MLYS free→QuarterlyIQ Insights · MLYS
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
*** Forward Looking Statements The Company cautions you that statements contained in this report regarding matters that are not historical facts are forward-looking statements. The forward-looking statements are based on the Company’s current beliefs and expectations and include, but are not limited to, the potential approval by the FDA of the lorundrostat NDA and the Company’s plans to commercially launch lorundrostat, the Company’s expectations with respect to finalizing an agreement with T…
Entry into a Material Definitive Agreement. Fourth Amendment to the License Agreement On June 2, 2026, Mineralys Therapeutics, Inc. (the “Company”) entered into a fourth amendment (the “Amendment”) to that certain License Agreement, dated July 9, 2020 and amended on November 24, 2020, June 15, 2023 and May 29, 2025 (the “License Agreement”), between the Company and Tanabe Pharma Corporation (“Tanabe”) for the purposes of terminating the Company’s potential future royalty payments to Tanabe an…
Other Events. On June 3, 2026, Mineralys Therapeutics, Inc. (“Mineralys” or the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with BofA Securities, Inc., Goldman Sachs & Co. LLC and Evercore Group L.L.C. (the “Underwriters”), relating to the issuance and sale of 5,660,378 shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”). The price in this offering is $26.50 per share. The Underwriters have agreed to purchase the shares f…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.